DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Cibc World Markets Corp

Cibc World Markets Corp increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 12.4% during the fourth quarter, HoldingsChannel reports. The fund owned 70,763 shares of the medical device company’s stock after buying an additional 7,786 shares during the period. Cibc World Markets Corp’s holdings in DexCom were worth $5,503,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DXCM. SlateStone Wealth LLC acquired a new stake in DexCom in the fourth quarter valued at $205,000. Patten & Patten Inc. TN grew its holdings in DexCom by 5.0% in the fourth quarter. Patten & Patten Inc. TN now owns 74,811 shares of the medical device company’s stock valued at $5,818,000 after purchasing an additional 3,570 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in DexCom by 30.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 16,159 shares of the medical device company’s stock valued at $1,257,000 after purchasing an additional 3,778 shares during the last quarter. Natixis Advisors LLC grew its holdings in DexCom by 446.6% in the fourth quarter. Natixis Advisors LLC now owns 193,532 shares of the medical device company’s stock valued at $15,051,000 after purchasing an additional 158,124 shares during the last quarter. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in DexCom in the fourth quarter valued at $793,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $73.38 on Thursday. The stock’s 50-day moving average is $83.51 and its 200-day moving average is $76.93. The company has a market cap of $28.67 billion, a price-to-earnings ratio of 51.31, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares of the company’s stock, valued at approximately $26,183,401.02. This trade represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock worth $8,044,178 in the last three months. 0.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Morgan Stanley upped their target price on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and upped their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Citigroup upped their price objective on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Finally, Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.